Active, not recruitingPhase 2NCT05270668
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
Studying Diffuse cutaneous systemic sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Principal Investigator
- Prometheus BiosciencesClinical Trials Call Center
- Intervention
- Tulisokibart(drug)
- Enrollment
- 154 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2029
Study locations (30)
- Mayo Clinic - Scottsdale ( Site 4014), Phoenix, Arizona, United States
- Pacific Arthritis Care Center ( Site 4008), Los Angeles, California, United States
- Cedars Sinai Medical Center ( Site 4010), Los Angeles, California, United States
- UCLA School of Medicine ( Site 4006), Los Angeles, California, United States
- Stanford Health Care ( Site 4009), Palo Alto, California, United States
- National Jewish Health Medical Center ( Site 4015), Denver, Colorado, United States
- Yale University ( Site 4017), New Haven, Connecticut, United States
- MedStar Georgetown University Hospital ( Site 4005), Washington D.C., District of Columbia, United States
- Johns Hopkins Asthma and Allergy Center [Baltimore, MD] ( Site 4018), Baltimore, Maryland, United States
- Massachusetts General Hospital ( Site 4003), Boston, Massachusetts, United States
- Boston University School of Medicine ( Site 4021), Boston, Massachusetts, United States
- University of Michigan Hospital ( Site 4001), Ann Arbor, Michigan, United States
- Rutgers Robert Wood Johnson Medical School ( Site 4013), New Brunswick, New Jersey, United States
- Hospital For Special Surgery ( Site 4020), New York, New York, United States
- Cleveland Clinic Foundation ( Site 4019), Cleveland, Ohio, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05270668 on ClinicalTrials.govOther trials for Diffuse cutaneous systemic sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07473154Controlling Hyperactive Immunity With Long-lived LymphocytesQuell Therapeutics Limited
- RECRUITINGPHASE1, PHASE2NCT06947473Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.Beijing GoBroad Hospital
- RECRUITINGPHASE2NCT05029336Autologous Stem Cell Transplant (ASCT) for Autoimmune DiseasesStephan Grupp MD PhD
- RECRUITINGPHASE2NCT07047690A Study of Nemolizumab for the Treatment of Adults With Systemic SclerosisGalderma R&D
- RECRUITINGPHASE2NCT07287670EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)Mediar Therapeutics
- RECRUITINGNCT07256418Transcriptomic Study of Cutaneous Fibroblasts in SclerodermaCentre Hospitalier Universitaire Dijon
- RECRUITINGPHASE1NCT07295847A Study of AZD0120 in Autoimmune DiseasesAstraZeneca
- RECRUITINGNANCT07292961Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed With SclerodermaHacettepe University